ICH = 2 Years after last approval based on study [Regulatives / Guidelines]

posted by Ohlbe – France, 2020-09-01 13:03 (1275 d 08:26 ago) – Posting: # 21906
Views: 1,903

Dear Brus,

❝ 2 Years for ICH? Where did you find that?


In ICH E6 (GCP), § 4.9.5:

Essential documents should be retained until at least 2-years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2-years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period however if required by the applicable regulatory requirements or by an agreement with the sponsor.

Cave: not 2 years after the end of the study, but 2 years after the last approval based on that study.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,912 posts in 4,806 threads, 1,638 registered users;
22 visitors (0 registered, 22 guests [including 7 identified bots]).
Forum time: 20:29 CET (Europe/Vienna)

Exploratory analysis: The art of finding a Rembrandt
in a Jackson Pollock.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5